SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-137586
Filing Date
2022-05-03
Accepted
2022-05-03 07:15:31
Documents
13
Period of Report
2022-05-03
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d241547d8k.htm   iXBRL 8-K 39003
2 EX-99.1 d241547dex991.htm EX-99.1 20929
  Complete submission text file 0001193125-22-137586.txt   198380

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20220503.xsd EX-101.SCH 2883
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20220503_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20220503_pre.xml EX-101.PRE 11725
7 EXTRACTED XBRL INSTANCE DOCUMENT d241547d8k_htm.xml XML 3476
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 22884576
SIC: 2834 Pharmaceutical Preparations